Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880032 | 0.91 | PTGDR2 (0.43) | PTGDR2HTR6AKR1C3AKR1C2CYP2D6 | |
| SCHEMBL12637102 | 0.91 | PTGDR2 (0.47) | PTGDR2 | |
| SCHEMBL12637098 | 0.91 | PTGDR2 (0.43) | PTGDR2HTR6AKR1C3AKR1C2 | |
| SCHEMBL1882598 | 0.90 | PTGDR2 (0.43) | PTGDR2CYP2C9 | |
| SCHEMBL14624590 | 0.87 | PTGDR2 (0.42) | PTGDR2HTR6CYP2C9 | |
| SCHEMBL12637104 | 0.86 | PTGDR2 (0.44) | PTGDR2HTR6AKR1C3AKR1C2F2RL3 | |
| SCHEMBL1880007 | 0.86 | PTGDR2 (0.41) | PTGDR2HTR6CYP2C9 | |
| SCHEMBL1880004 | 0.86 | PTGDR2 (0.41) | PTGDR2HTR6CYP2C9 | |
| SCHEMBL16495274 | 0.85 | PTGDR2 (0.38) | PTGDR2CYP2D6CYP2C9F2RL3 | |
| SCHEMBL1879538 | 0.83 | EGFR (0.43) | PTGDR2HTR6AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | AR, SHBG, CYP17A1 | PTGDR2 437/4885HTR6 2621/4885AKR1C3 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.